Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 2/20 | 0.80 |
| ▸ | DRD4 | P21917 | 2/20 | 0.80 |
| ▸ | DRD3 | P35462 | 2/20 | 0.80 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.68 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.63 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.63 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.59 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.59 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7543876 | 1.00 | DRD2 (0.80) | DRD2DRD4DRD3MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL7544278 | 0.98 | DRD2 (0.78) | DRD2DRD4DRD3MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL7543024 | 0.98 | DRD2 (0.78) | DRD2DRD4DRD3MTNR1AMTNR1B | |
| SCHEMBL8044481 | 0.89 | DRD2 (1.00) | DRD2DRD4DRD3MTNR1AMTNR1B | |
| SCHEMBL8044480 | 0.89 | DRD2 (1.00) | DRD2DRD4DRD3MTNR1AMTNR1B | |
| SCHEMBL8044484 | 0.89 | DRD2 (1.00) | DRD2DRD4DRD3MTNR1AMTNR1B | |
| Hydrochloric Acid SCHEMBL10849302 | 0.88 | DRD2 (0.97) | DRD2DRD4DRD3MTNR1AMTNR1B | |
| SCHEMBL9355070 | 0.86 | MTNR1A (0.66) | DRD2DRD4DRD3MTNR1AMTNR1B | |
| SCHEMBL8892023 | 0.83 | DRD2 (0.82) | DRD2DRD4DRD3MTNR1AMTNR1B | |
| SCHEMBL8890686 | 0.83 | MTNR1A (0.66) | DRD2DRD4DRD3MTNR1AMTNR1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0883599-B1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | claimed |
| EP-0883599-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1998-12-16 | — | — | EP | claimed |
| US-5807897-A | MUSCULAR DISORDERS | ZENECA LIMITED (GB) | 1998-09-15 | — | — | US | claimed |
| WO-1997031887-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1997-09-04 | — | — | WO | claimed |
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | ASTRAZENECA AB (SE) | 2009-04-16 | — | — | US | disclosed |
| EP-1888518-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | AstraZeneca AB (SE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006126938-A1 | NOVEL 8-SULFONYL-3 AMINOSUBSTITUTED CHROMAN OR TETRAHYDRONAPHTALENE DERIVATIVES MODULATING THE 5HT6 RECEPTOR | ASTRAZENECA AB (SE) | 2006-11-30 | — | — | WO | disclosed |
| EP-0883599-B1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ASTRAZENECA AB (SE) | 2002-06-05 | — | — | EP | disclosed |
| EP-0883599-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1998-12-16 | — | — | EP | disclosed |
| US-5807897-A | MUSCULAR DISORDERS | ZENECA LIMITED (GB) | 1998-09-15 | — | — | US | disclosed |
| WO-1997031887-A1 | AMINOTETRALIN DERIVATIVES AND COMPOSITIONS AND METHOD OF USE THEREOF | ZENECA LIMITED (GB) | 1997-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099187-A1 | Novel 8-Sulfonyl-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5HT6 Receptor | HTR6, HTR1D, HTR1A | DRD2 56/4885DRD4 98/4885DRD3 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.